Synapse - Phase I first-in-class trial of MCARH109, a G protein coupled receptor class C group 5 member D (GPRC5D) targeted CAR T cell therapy in patients with relapsed or refractory multiple myeloma

Phase I first-in-class trial of MCARH109, a G protein coupled receptor class C group 5 member D (GPRC5D) targeted CAR T cell therapy in patients with relapsed or refractory multiple myeloma Meeting Abstract

Authors:	Mailankody, S.; Diamonte, C.; Fitzgerald, L.; Kane, P.; Wang, X.; Sikder, D. S.; Senechal, B.; Bermudez, V. P.; Frias, D.; Morgan, J.; Grant, P.; Purdon, T. J.; Hosszu, K.; Devlin, S. M.; Shah, U. A.; Landa, J.; Lesokhin, A.; Korde, N.; Hassoun, H.; Tan, C.; Hultcrantz, M.; Shah, G. L.; Landau, H. J.; Chung, D. J.; Scordo, M.; Roshal, M.; Landgren, O.; Dogan, A.; Giralt, S. A.; Park, J. H.; Rivière, I.; Brentjens, R. J.; Smith, E. L.
Abstract Title:	Phase I first-in-class trial of MCARH109, a G protein coupled receptor class C group 5 member D (GPRC5D) targeted CAR T cell therapy in patients with relapsed or refractory multiple myeloma
Meeting Title:	63rd Annual Meeting of the American Society of Hematology (ASH)
Journal Title:	Blood
Volume:	138
Issue:	Suppl. 1
Meeting Dates:	2021 Dec 11-14
Meeting Location:	Atlanta, GA
ISSN:	0006-4971
Publisher:	American Society of Hematology
Date Published:	2021-11-23
Language:	English
ACCESSION:	WOS:000736398803125
DOI:	10.1182/blood-2021-153204
PROVIDER:	wos
Notes:	Meeting Abstract: 827 -- Hybrid meeting, also took place online -- Source: Wos